CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 50 enrolled
Drug / intervention
Naltrexone +1 moredrug
Likely dose
Naltrexone 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01052831
NCT01052831Phase 4Completed
CompareCT.gov

Randomized, Double-blind, Placebo-controlled Study of Naltrexone for Impulse Control Disorders in Parkinson's Disease

University of Pennsylvania·interventional·Posted Jan 20, 2010·Updated Aug 6, 2015

In Brief

A Phase 4 clinical trial evaluating Naltrexone and Placebo for Impulse Control Disorder and Parkinson Disease. Completed, enrolled 50 participants across 1 site.

Detailed Summary

This study will evaluate the effectiveness of naltrexone in reducing ICD symptoms in Parkinson's disease patients taking a dopamine agonist.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImpulse Control Disorder, Parkinson Disease
CountriesUnited States
CollaboratorsMichael J. Fox Foundation for Parkinson's Research

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 20, 2010
Enrollment StartNov 1, 2009
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 16.4 years ago

Interventions

Naltrexonedrug

50-100 mg qd for 8 weeks

Placebodrug

50-100 mg qd for 8 weeks